問卷

TPIDB > Principal Investigator

Principal Investigator


MacKay Memorial Hospital (在職)

Division of General Internal Medicine

Division of General Internal Medicine

Digestive System Department

MacKay Memorial Hospital

Division of General Internal Medicine

Digestive System Department

更新時間:2023-09-19

章振旺
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

15Cases

2025-09-01 - 2032-10-06

Phase II/III

Active
A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol to Evaluate the Efficacy and Safety of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
  • Condition/Disease

    Severely Active Crohn's Disease

  • Test Drug

    Icotrokinra

Participate Sites
5Sites

Recruiting5Sites

2022-12-01 - 2029-04-01

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2025-06-01 - 2029-01-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2024-04-12 - 2028-12-31

Phase II

Active
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study Evaluating the Efficacy and Safety of GS-1427 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)
  • Condition/Disease

    Moderately to Severely Active Ulcerative Colitis

  • Test Drug

    GS-1427

Participate Sites
8Sites

Recruiting8Sites

2017-01-22 - 2023-12-22

Phase III

Active
A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis
  • Condition/Disease

    Ulcerative Colitis

  • Test Drug

    Filgotinib

Participate Sites
13Sites

Recruiting9Sites

Terminated3Sites

2025-07-01 - 2029-03-07

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2024-04-12 - 2028-12-31

Phase II

Active
A Multicenter, Randomized, Double-blind, 2-Part Phase 2 Study to Evaluate the Efficacy and Safety of GS-1427 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)
  • Condition/Disease

    Moderately to Severely Active Ulcerative Colitis

  • Test Drug

    GS-1427

Participate Sites
8Sites

Recruiting8Sites

2015-11-01 - 2018-03-31

Phase III

A Phase 3b Open-Label Study of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 weeks in Subjects with Chronic Genotype 1 or 2 Hepatitis C Virus (HCV) and Hepatitis B Virus (HBV) Coinfection
  • Condition/Disease

    Antiviral efficacy of chronic infection with hepatitis C virus (HCV) of genotype 1 or 2

  • Test Drug

    Harvoni®

Participate Sites
15Sites

Terminated14Sites

2011-08-30 - 2014-07-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
17Sites

Terminated17Sites

1 2